AG
HAE icon

Aperio Group’s Haemonetics HAE Stock Holding History

Aperio Group’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1.41M Buy
11,845
+2,069
+21% +$223K ﹤0.01% 1405
2020
Q3 		$853K Sell
9,776
-1,470
-13% -$128K ﹤0.01% 1521
2020
Q2 		$1.01M Sell
11,246
-1,569
-12% -$158K ﹤0.01% 1407
2020
Q1 		$1.28M Buy
12,815
+1,002
+8% +$109K 0.01% 1203
2019
Q4 		$1.36M Sell
11,813
-1,552
-12% -$188K ﹤0.01% 1277
2019
Q3 		$1.69M Buy
13,365
+1,604
+14% +$204K 0.01% 1129
2019
Q2 		$1.42M Sell
11,761
-5,420
-32% -$533K 0.01% 1224
2019
Q1 		$1.5M Sell
17,181
-3,935
-19% -$358K 0.01% 1169
2018
Q4 		$2.11M Buy
21,116
+3,670
+21% +$386K 0.01% 967
2018
Q3 		$2M Buy
17,446
+5,579
+47% +$578K 0.01% 1062
2018
Q2 		$1.06M Buy
11,867
+269
+2% +$22.7K 0.01% 1345
2018
Q1 		$849K Buy
11,598
+213
+2% +$14.6K ﹤0.01% 1419
2017
Q4 		$661K Buy
11,385
+715
+7% +$37.6K ﹤0.01% 1565
2017
Q3 		$479K Sell
10,670
-25
-0.2% -$1.04K ﹤0.01% 1685
2017
Q2 		$422K Buy
10,695
+1,393
+15% +$57.2K ﹤0.01% 1729
2017
Q1 		$377K Sell
9,302
-16
-0.2% -$625 ﹤0.01% 1711
2016
Q4 		$375K Buy
9,318
+2,015
+28% +$76K ﹤0.01% 1678
2016
Q3 		$264K Buy
+7,303
New +$251K ﹤0.01% 1780
2016
Q2 		– Sell
-8,275
Closed -$289K – 2017
2016
Q1 		$289K Sell
8,275
-276
-3% -$8.91K ﹤0.01% 1684
2015
Q4 		$276K Sell
8,551
-3,900
-31% -$127K ﹤0.01% 1668
2015
Q3 		$402K Sell
12,451
-2,447
-16% -$92.1K ﹤0.01% 1423
2015
Q2 		$616K Buy
14,898
+414
+3% +$17.5K 0.01% 1214
2015
Q1 		$651K Buy
14,484
+1,244
+9% +$52K 0.01% 1132
2014
Q4 		$495K Buy
13,240
+3,592
+37% +$132K 0.01% 1232
2014
Q3 		$337K Sell
9,648
-39
-0.4% -$1.39K ﹤0.01% 1331
2014
Q2 		$342K Buy
+9,687
New +$324K 0.01% 1319

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Aperio Group's HAE Position: Q4 2020 in Review

Aperio Group increased its Haemonetics (HAE) stake by 21% in Q4 2020, buying an estimated $223K and bringing the position to 11,845 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1405.

Aperio Group first reported a position in HAE in Q2 2014 and has held it in 26 quarters since. The position peaked at $2.11M in Q4 2018. 286 funds tracked by Wall St. Rank hold HAE as of Q4 2020.

  • Aperio Group held 11,845 shares of Haemonetics worth $1.41M as of Q4 2020.
  • Aperio Group bought 2,069 Haemonetics shares in Q4 2020, an estimated $223K.
  • Haemonetics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1405 holding.
  • Aperio Group first reported a position in Haemonetics in Q2 2014 and has held it in 26 quarters since.
  • Aperio Group's Haemonetics position peaked at $2.11M in Q4 2018.
  • 286 funds tracked by Wall St. Rank held Haemonetics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.